Arthur Tzianabos insider trades: Stoke Therapeutics (STOK) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Arthur reports to the SEC
Open-market buys and sales
18 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | STOK | ↓ Sell | 4,355 | $40.00 | $174K | Direct | Mar 12, 2026 (2d) |
| Mar 25, 2024 | QTTB | ↓ Sell | 265 | $24.20 | $6K | Direct | Aug 14, 2024 (142d) |
| Jan 9, 2024 | FIXX | ↓ Sell | 13,037 | $0.57 | $7K | Direct | Feb 15, 2024 (37d) |
| Jan 9, 2023 | FIXX | ↓ Sell | 10,616 | $1.39 | $15K | Direct | Jan 11, 2023 (2d) |
| Jan 5, 2022 | FIXX | ↓ Sell | 5,354 | $3.78 | $20K | Direct | Jan 12, 2022 (7d) |
| Feb 19, 2021 | STOK | ↓ Sell | 10,000 | $60.67 | $607K | Direct | Feb 23, 2021 (4d) |
| Nov 23, 2020 | STOK | ↓ Sell | 20,000 | $46.03 | $921K | Direct | Nov 25, 2020 (2d) |
| Feb 3, 2020 | FIXX | ↓ Sell | 12,500 | $16.16 | $202K | Direct | Feb 5, 2020 (2d) |
| Jan 2, 2020 | FIXX | ↓ Sell | 12,500 | $20.50 | $256K | Direct | Jan 3, 2020 (1d) |
| Dec 2, 2019 | FIXX | ↓ Sell | 25,000 | $16.15 | $404K | Direct | Dec 3, 2019 (1d) |
| Oct 1, 2019 | FIXX | ↓ Sell | 12,500 | $17.40 | $217K | Direct | Oct 2, 2019 (1d) |
| Sep 3, 2019 | FIXX | ↓ Sell | 12,500 | $18.75 | $234K | Direct | Sep 5, 2019 (2d) |
| Aug 1, 2019 | FIXX | ↓ Sell | 12,500 | $17.37 | $217K | Direct | Aug 5, 2019 (4d) |
| Jul 1, 2019 | FIXX | ↓ Sell | 12,500 | $18.98 | $237K | Direct | Jul 3, 2019 (2d) |
| Jun 3, 2019 | FIXX | ↓ Sell | 12,500 | $19.86 | $248K | Direct | Jun 5, 2019 (2d) |
| Apr 9, 2015 | OVAS | ↑ Buy | 225 | $28.77 | $6K | Direct | Apr 9, 2015 (0d) |
| Apr 8, 2015 | OVAS | ↑ Buy | 175 | $28.04 | $5K | Direct | Apr 8, 2015 (0d) |
| Sep 12, 2013 | OVAS | ↑ Buy | 1,000 | $10.32 | $10K | by IRA | Sep 12, 2013 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other STOK insiders
Open-market trades in the last 12 months
About Arthur Tzianabos's insider trades
Arthur Tzianabos is Interim Executive Chair at Stoke Therapeutics (STOK). Since Sep 12, 2013, Arthur has reported 3 open-market purchases worth $22K and 15 sales worth $3.8M on SEC Form 4. In the last 12 months: 1 sale ($174K).
Their filings also include grants and awards (26 filings), option exercises (9 filings), shares returned to the company (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every STOK insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.